{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:07:15Z","timestamp":1780409235509,"version":"3.54.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The discrepancy between the biomarkers of disease\u2019s activity in acromegalic patients (GH and IGF-1) is almost frequent representing a challenge for the development of comorbidities in the long term. The aim of this study was to evaluate the prevalence and severity of metabolic comorbidities (diabetes, hypertension, and dyslipidemia) in surgically treated acromegalic patients with disease control and discordant GH and\/or IGF-1 levels compared with those with concordant values.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Retrospective monocentric observational study on acromegalic surgically treated patients with biochemical remission (group A) or mild discordant GH or IGF-1 levels (group B). Metabolic complications and medical therapy were assessed at diagnosis and at the last follow-up visit. Severity of the disease was set for drug titration or shift to another molecule or more than before.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 18 patients that met the inclusion criteria [group A: nine patients; group B: nine patients, follow-up 7 years (IQR 5.0;11.25)]. The prevalence of female patients was significantly higher in the remission group compared with the discordant group (p &amp;lt; 0.02). Considering metabolic complications, at the last follow-up, 61.1% was affected by hypertension, 33.3% by diabetes, and 61.1% by dyslipidemia, without differences between groups. Drug characteristics (dose, shift, number) during the follow-up did not differ significantly between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Metabolic complications, mainly dyslipidemia, are frequent in cured acromegalic patients, but GH\/IGF-1 discrepancy does not seem to represent a risk factor for their presence or persistence. More extended studies are needed to confirm our results in a long-term period.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1256975","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T09:20:33Z","timestamp":1695892833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study"],"prefix":"10.3389","volume":"14","author":[{"given":"Martina","family":"Romanisio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Pitino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pizzolitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Costelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Antoniotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marzullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Aimaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Prodam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39375","article-title":"Acromegaly: pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Investig"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40618-018-0928-7","article-title":"Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy","volume":"42","author":"Caputo","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0253","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ecl.2019.08.008","article-title":"Hypertension and acromegaly","volume":"48","author":"Puglisi","year":"2019","journal-title":"Endocrinol Metab Clin N Am"},{"key":"B10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","article-title":"Current and emerging aspects of diabetes mellitus in acromegaly","volume":"27","author":"Maffezzoni","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061376","article-title":"Regulation of GH and GH signaling by nutrients","volume":"10","author":"Caputo","year":"2021","journal-title":"Cells"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2570","article-title":"Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control","volume":"95","author":"Berg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0369-1","article-title":"Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly na\u00efve to medical therapy and radiation: what to follow, GH or IGF-1 values","volume":"15","author":"Brzana","year":"2012","journal-title":"Pituitary"},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3397200","article-title":"Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study","volume":"43","author":"Colao","year":"2020","journal-title":"J Endocrinol Investig"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02387-1","article-title":"Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database","volume":"70","author":"Amodru","year":"2020","journal-title":"Endocrine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of cardiology\/American heart association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-1064","article-title":"French Acromegaly Registry Group. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13129","article-title":"The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis","volume":"85","author":"Kanakis","year":"2016","journal-title":"Clin Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/clinem\/dgaa859","article-title":"Discordant GH and IGF-1 results in treated acromegaly: impact of GH cutoffs and mean values assessment","volume":"106","author":"Campana","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01830-6","article-title":"Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy","volume":"45","author":"Bona","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1210\/jc.2007-2104","article-title":"Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly","volume":"93","author":"Alexopoulou","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1530\/EJE-11-0098","article-title":"Clinical and metabolic characteristics of acromegalic patients with high IGF1\/normal GH levels during somatostatin analog treatment","volume":"164","author":"Matta","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1210\/jc.2014-2259","article-title":"Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk","volume":"99","author":"Reyes-Vidal","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1530\/EJE-17-0546","article-title":"Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study","volume":"178","author":"Dal","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1210\/er.2003-0035","article-title":"Estrogen regulation of growth hormone action","volume":"25","author":"Leung","year":"2004","journal-title":"Endocr Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12020-020-02206-7","article-title":"Acromegaly in the elderly patients","volume":"68","author":"Ambrosio","year":"2020","journal-title":"Endocrine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000514434","article-title":"Dynamic tests in pituitary endocrinology: pitfalls in interpretation during aging","volume":"112","author":"Caputo","year":"2022","journal-title":"Neuroendocrinology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01063-x","article-title":"Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review","volume":"23","author":"Agrawal","year":"2020","journal-title":"Pituitary"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab069","article-title":"Predictors for remission after transsphenoidal surgery in acromegaly: A Dutch multicenter study","volume":"106","author":"Coopmans","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1256975\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T09:20:35Z","timestamp":1695892835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1256975\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":33,"alternative-id":["10.3389\/fendo.2023.1256975"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1256975","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"article-number":"1256975"}}